Vertex Pharmaceuticals’ CASGEVY Receives FDA Label Expansion for Over 5,500 US Children with Sickle Cell and Beta-Thalassemia, Driving Soaring Sales

August 23, 2026

ScanX USA

Overview

Vertex Pharmaceuticals’ gene therapy, CASGEVY (exagamglogene autotemcel), received FDA label expansion for patients aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). This approval makes CASGEVY the first gene therapy for these conditions in children 2 years and older, expanding treatment access to approximately 5,500 new pediatric patients in the US. CASGEVY’s sales are surging, reporting $76.4 million in Q2, a 78.1% increase QoQ and 151.3% YoY, as Vertex expands its network of over 75 authorized treatment centers and progresses regulatory reviews in Saudi Arabia and the UK.

In Depth

Key Findings

Vertex Pharmaceuticals’ groundbreaking gene therapy, CASGEVY (exagamglogene autotemcel), has secured an expanded indication approval from the U.S. Food and Drug Administration (FDA) for pediatric patients aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). This landmark decision is set to make the innovative treatment accessible to an additional 5,500 children across the United States, positioning CASGEVY as the first and only FDA-approved gene therapy for both conditions in this younger patient population. This regulatory achievement has significantly accelerated the therapy’s commercial traction, with Q2 revenues for CASGEVY reaching $76.4 million, reflecting a substantial 78.1% quarter-over-quarter and 151.3% year-over-year increase.

Technical / Clinical Details

CASGEVY employs an autologous ex vivo CRISPR/Cas9 gene-editing approach, where a patient’s own hematopoietic stem cells are modified to reactivate the production of functional fetal hemoglobin (HbF), thereby addressing the underlying genetic cause of SCD and TDT. The therapy aims to eliminate or significantly reduce the need for chronic blood transfusions and alleviate vaso-occlusive crises (VOCs) associated with SCD. The FDA’s label expansion is supported by compelling safety and efficacy data demonstrated in clinical trials involving pediatric patients aged 2 and older, promising potentially lifelong therapeutic benefits for children suffering from these severe hematological disorders. Vertex is actively expanding its network, operating over 75 authorized treatment centers across the U.S. to ensure broader patient access.

Background & Context

Sickle cell disease and beta-thalassemia are debilitating inherited blood disorders that historically have had limited curative options, particularly for pediatric patients who often face complex disease management and a lifetime of chronic burdens. One-time gene therapies like CASGEVY represent a revolutionary shift in treatment, offering the potential for a functional cure and dramatically improving patient quality of life. Vertex Pharmaceuticals, renowned for its success in cystic fibrosis therapies, has strategically invested heavily in advanced modalities such as CRISPR gene editing and stem cell therapies to diversify its business. The success of CASGEVY indicates that its venture into the gene therapy space is yielding significant returns, strengthening its overall portfolio and market position.

Strategic Significance & Outlook

The FDA’s label expansion for CASGEVY marks a crucial commercial milestone for Vertex Pharmaceuticals, solidifying its leadership in the burgeoning gene therapy market. The broader patient eligibility is expected to be a major driver of future revenue growth. Furthermore, ongoing regulatory reviews in Saudi Arabia and the United Kingdom signal promising global expansion opportunities. However, challenges related to the therapy’s high cost, manufacturing complexity, and limited treatment center capacity remain key considerations for broader adoption. Vertex is poised for additional growth catalysts in late 2026 and 2027, including the PDUFA target action date for POVETACEPT (November 30, 2026) and the anticipated completion of the Crinetics acquisition, underscoring the company’s aggressive growth strategy.

Source: https://scanx.trade/stock-market-news/companies/fda-approves-casgevy-for-young-children-with-sickle-cell-disease/44493938

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.